Endovascular treatment for acute ischemic stroke patients: implications and interpretation of IMS III, MR RESCUE, and SYNTHESIS EXPANSION trials: A report from the Working Group of International Congress of Interventional Neurology

Qureshi, Adnan I; Abd-Allah, Foad; Aleu, Aitziber; Connors, John J; Hanel, Ricardo A; Hassan, Ameer E; Hussein, Haitham M; Janjua, Nazli A; Khatri, Rakesh; Kirmani, Jawad F; Mazighi, Mikael; Mattle, Heinrich; Miley, Jefferson T; Nguyen, Thanh N; Rodriguez, Gustavo J; Shah, Qaisar A; Siddiqui, Adnan H; Suarez, Jose I; Suri, M Fareed K and Tolun, Reha (2014). Endovascular treatment for acute ischemic stroke patients: implications and interpretation of IMS III, MR RESCUE, and SYNTHESIS EXPANSION trials: A report from the Working Group of International Congress of Interventional Neurology. Journal of vascular and interventional neurology, 7(1), pp. 56-75. Zeenat Qureshi Stroke Research Center

[img] Text
jvin-7-1-56.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (296kB)

OBJECTIVE

The results of Interventional Management of Stroke (IMS) III, Magnetic Resonance and REcanalization of Stroke Clots Using Embolectomy (MR RESCUE), and SYNTHESIS EXPANSION trials are expected to affect the practice of endovascular treatment for acute ischemic stroke. The purpose of this report is to review the components of the designs and methods of these trials and to describe the influence of those components on the interpretation of trial results.

METHODS

A critical review of trial design and conduct of IMS III, MR RESCUE, and SYNTHESIS EXPANSION is performed with emphasis on patient selection, shortcomings in procedural aspects, and methodology of data ascertainment and analysis. The influence of each component is estimated based on published literature including multicenter clinical trials reporting on endovascular treatment for acute ischemic stroke and myocardial infarction.

RESULTS

We critically examined the time interval between symptom onset and treatment and rates of angiographic recanalization to differentiate between "endovascular treatment" and "parameter optimized endovascular treatment" as it relates to the IMS III, MR RESCUE, and SYNTHESIS EXPANSION trials. All the three trials failed to effectively test "parameter optimized endovascular treatment" due to the delay between symptom onset and treatment and less than optimal rates of recanalization. In all the three trials, the magnitude of benefit with endovascular treatment required to reject the null hypothesis was larger than could be expected based on previous studies. The IMS III and SYNTHESIS EXPANSION trials demonstrated that rates of symptomatic intracerebral hemorrhages subsequent to treatment are similar between IV thrombolytics and endovascular treatment in matched acute ischemic stroke patients. The trials also indirectly validated the superiority/equivalence of IV thrombolytics (compared with endovascular treatment) in patients with minor neurological deficits and those without large vessel occlusion on computed tomographic/magnetic resonance angiography.

CONCLUSIONS

The results do not support a large magnitude benefit of endovascular treatment in subjects randomized in all the three trials. The possibility that benefits of a smaller magnitude exist in certain patient populations cannot be excluded. Large magnitude benefits can be expected with implementation of "parameter optimized endovascular treatment" in patients with ischemic stroke who are candidates for IV thrombolytics.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Neurology

UniBE Contributor:

Mattle, Heinrich

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1941-5893

Publisher:

Zeenat Qureshi Stroke Research Center

Language:

English

Submitter:

Valentina Rossetti

Date Deposited:

11 Mar 2015 17:08

Last Modified:

05 Dec 2022 14:42

PubMed ID:

24920991

Uncontrolled Keywords:

Acute ischemic stroke, endovascular treatment, intravenous thrombolysis, thrombectomy, randomized clinical trial, stroke, death

BORIS DOI:

10.7892/boris.64314

URI:

https://boris.unibe.ch/id/eprint/64314

Actions (login required)

Edit item Edit item
Provide Feedback